Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
- Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
- Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
- Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
- Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
- Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
- Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
- FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
- Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
- Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
- Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
- Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
April 3, 2024
- Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
- Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
- MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
- Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
- Cheplapharm to Take Over 5 Brands from Clinigen in Japan
April 2, 2024
- Aculys Pharma Poaches Takeda Veteran as New CEO
April 2, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…